Seek Returns

BMY vs. PFE: Bristol-Myers Squibb vs. Pfizer Stock Comparison

How do Bristol-Myers Squibb (BMY) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bristol-Myers Squibb (BMY) and Pfizer (PFE) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
Profile ItemBMYPFE
NameBristol-Myers Squibb CompanyPfizer Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization127.02 billion USD167.52 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateJune 1, 1972June 1, 1972
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BMY
PFE
GSPC
Loading price history…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bristol-Myers Squibb (BMY) and Pfizer (PFE). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bristol-Myers Squibb (BMY) and Pfizer (PFE). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
MetricBMYPFE
Total Return (1Y)38.62%28.65%
Total Return (3Y, Annualized)12.29%6.41%
Total Return (5Y, Annualized)5.09%-3.98%

Risk Profile

Drawdown History

BMY
PFE
GSPC
Loading price history…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bristol-Myers Squibb (BMY) and Pfizer (PFE). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
MetricBMYPFE
Volatility (1Y, Annualized)28.01%21.72%
Beta (5Y)0.190.35
Max Drawdown (5Y)-47.67%-58.96%
Avg. Volume (3M)10.85M33.67M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BMY and PFE are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
MetricBMYPFE
Sharpe Ratio (1Y)1.231.12
Sortino Ratio (1Y)1.951.73

Profitability

ROE (TTM)

Bristol-Myers Squibb (BMY) at 44.01% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for BMY.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.01%

Max
109.18%
BMY
44.01%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max
109.18%
Q3
6.23%
PFE
4.47%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bristol-Myers Squibb (BMY) at 18.47% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.47%

BMY
18.47%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max
18.05%
PFE
6.34%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Bristol-Myers Squibb (BMY) at 33.79% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.79%

Max
83.12%
BMY
33.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max
83.12%
PFE
33.38%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
MetricBMYPFE
ROE (TTM)44.01%4.47%
ROA (TTM)10.90%5.59%
Net Margin (TTM)18.47%6.34%
Operating Margin (TTM)33.79%33.38%
Gross Margin (TTM)70.50%74.90%

Growth

Revenue Growth

Bristol-Myers Squibb (BMY) at -0.22% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
MetricBMYPFE
Revenue Growth (YoY)-0.22%-1.65%
Revenue Growth (3Y CAGR)1.45%-14.80%
EPS Growth (YoY)---3.55%
EPS Growth (3Y CAGR)5.46%-37.12%

Financial Strength

Current Ratio (MRQ)

Both Bristol-Myers Squibb (BMY) at 1.59 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.59

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BMY
1.59
Min
0.10

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
PFE
1.42
Min
0.10
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but BMY is more stretched: Pfizer (PFE) at 0.71 sits in the higher-leverage quartile and Bristol-Myers Squibb (BMY) at 1.91 is above its industry benchmark range.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.91

BMY
1.91
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max
1.42
PFE
0.71
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
MetricBMYPFE
Current Ratio (MRQ)1.591.42
Debt / Equity (MRQ)1.910.71
Net Debt / EBITDA1.771.97

Dividends

Dividend Yield (TTM)

Both Bristol-Myers Squibb (BMY) at 3.99% and Pfizer (PFE) at 7.30% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.99%

BMY
3.99%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE
7.30%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Bristol-Myers Squibb (BMY) reports 55.88%, ranking against industry peers normally.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

55.88%

BMY
55.88%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE
245.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
MetricBMYPFE
Dividend Yield (TTM)3.99%7.30%
Dividend Payout Ratio (TTM)55.88%245.71%

Valuation

P/E Ratio (TTM)

Both Bristol-Myers Squibb (BMY) at 13.78 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.78

Max
85.34
Q3
43.46
Median
26.69
BMY
13.78
Q1
13.30
Min
0.07

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max
85.34
Q3
43.46
PFE
41.99
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Both Bristol-Myers Squibb (BMY) at 2.54 and Pfizer (PFE) at 2.63 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.54

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
BMY
2.54
Min
0.01

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
PFE
2.63
Min
0.01
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Bristol-Myers Squibb (BMY) at 5.43 and Pfizer (PFE) at 1.88 are valued close to their industries’ norm against book — neither stands out from peers.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.43

Max
13.53
Q3
6.54
BMY
5.43
Median
3.25
Q1
1.69
Min
-5.59

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max
13.53
Q3
6.54
Median
3.25
PFE
1.88
Q1
1.69
Min
-5.59
Loading chart…
Bristol-Myers Squibb (BMY) vs. Pfizer (PFE): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bristol-Myers Squibb (BMY) and Pfizer (PFE)
MetricBMYPFE
P/E Ratio (TTM)13.7841.99
P/S Ratio (TTM)2.542.63
P/B Ratio (MRQ)5.431.88
Free Cash Flow Yield (TTM)5.01%7.76%